Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.57 |
| ▸ | LPL | P06858 | 7/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22035758 | 1.00 | LIPG (0.57) | LIPGLPLJAK2BTKHSD17B1 | |
| SCHEMBL20904793 | 0.89 | LIPG (0.46) | LIPGLPLJAK2BTKTAAR1 | |
| SCHEMBL23676982 | 0.89 | LIPG (0.49) | LIPGLPLDGAT1 | |
| SCHEMBL20904636 | 0.89 | LIPG (0.62) | LIPGLPLJAK2BTKPDGFRB | |
| SCHEMBL23676989 | 0.88 | LIPG (0.46) | LIPGLPL | |
| SCHEMBL3794764 | 0.87 | LIPG (0.57) | LIPGLPLJAK2BTKHSD17B1 | |
| SCHEMBL30514721 | 0.87 | LIPG (0.57) | LIPGLPLJAK2BTKHSD17B1 | |
| SCHEMBL20654912 | 0.87 | LIPG (0.46) | LIPGLPLDGAT1 | |
| SCHEMBL21689798 | 0.84 | LPL (0.44) | LIPGLPLDGAT1 | |
| SCHEMBL20904632 | 0.84 | PGR (0.43) | LIPGLPLJAK2BTKPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11706977-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-11706977-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-20190214570-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11706977-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CRY1, CYP1B1, CYP1A1 | LIPG 3920/4885LPL 2843/4885JAK2 2472/4885 |
| US-20190214570-A1 | HETEROCYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND | CRY1, CYP1B1, CYP1A1 | LIPG 3920/4885LPL 2843/4885JAK2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.